New obesity drug tested in 348 people: which injection works best?
NCT ID NCT07226778
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested how the experimental drug maridebart cafraglutide (AMG 133) is absorbed when given as two different injections. 348 adults with overweight or obesity received a single dose. The main goal was to measure drug levels in the blood, not weight loss. Results will guide future studies on this potential obesity treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
maridebart cafraglutide (AMG 133)
What this could lead to
If successful, this could help determine the best way to give maridebart cafraglutide for weight management, potentially leading to a more effective obesity treatment.
What could go wrong
This is an early Phase 1 study focused on drug absorption, not on weight loss or safety. It may not lead to a proven treatment, and side effects or lack of efficacy could emerge in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801-2658, United States
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4989, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
-
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, 53704-2526, United States